Search results for "pertosse"

showing 2 items of 2 documents

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine.

1994

The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-lin…

Bordetella pertussisbiologybusiness.industryDiphtheriaFilamentous haemagglutinin adhesinbiology.organism_classificationmedicine.diseasePertussis toxincomplex mixturesVirologyVaccinationVaccino pertosse; immunogenicità; tossina; vaccinazione; bambiniPediatrics Perinatology and Child HealthImmunologymedicinePertussis vaccinePertactinBORDETELLA-PERTUSSISbusinessWhooping coughmedicine.drug
researchProduct

ACELLULAR PERTUSSIS VACCINE COMPOSED OF GENETICALLY INACTIVATED PERTUSSIS TOXIN: SAFETY AND IMMUNOGENICITY IN 12- TO 24- AND 2-TO 4-MONTH-OLD CHILDREN

1992

To determine whether a nontoxic derivative of pertussis toxin obtained by recombinant DNA technology, PT-9K/129G, is a good candidate for a new pertussis vaccine, we examined the safety and the immunogenicity in children of a vaccine containing 15 micrograms of PT-9K/129G protein and 0.5 mg of aluminum hydroxide per dose. Fifty-three children 12 to 24 months of age and 21 infants aged 2 to 4 months were injected with two and three doses, respectively. The vaccine did not induce significant local or systemic reactions and elicited an increase of antibody titer in more than 98% of the children. The geometric mean of the toxin-neutralizing titers increased after each dose and was 85 units in c…

Whooping Coughpertussis; vaccineEnzyme-Linked Immunosorbent Assayi mmunitàPertussis toxinBordetella pertussisimmunogenicitàvaccinemedicineHumansVirulence Factors Bordetellaprova clinicaWhooping coughpertossePertussis VaccineVaccines Synthetictossinabiologybusiness.industryImmunogenicitypertussisVaccinationAntibody titerVaccinoInfantbiology.organism_classificationmedicine.diseaseVaccino; pertosse; tossina; i mmunità; prova clinica; immunogenicità; sicurezzaAntibodies BacterialVirologysicurezzaVaccinationBordetellaTiterPertussis ToxinAntibody FormationPediatrics Perinatology and Child HealthImmunologyDrug EvaluationPertussis vaccinebusinessmedicine.drug
researchProduct